Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm

Delivering Chemotherapy Drugs Directly into Cancer Cells While Minimizing Harm Ren Homan, Ph.D., Co-Founder of Peptinovo Biopharma and Steve Tokarz, CEO of Peptinovo Biopharma   

Peptinovo Biopharma’s Targeted Cancer Drug Platform Approved for Clinical Trials

Peptinovo Biopharma, an Ann Arbor–based biotechnology company pioneering targeted cancer therapies through its first-of-its-kind proprietary PALM™ nanotechnology, today announced it has received approval to initiate its first human clinical trials in Australia. The milestone clears the way for the company to begin enrolling cancer patients in the coming months.

Founder’s Story: Ren Homan

Dr. Ren Homan, Chief Scientific Officer and President of Peptinovo Biopharma, has had an extensive and dynamic career in the biopharmaceutical industry. From its inception to the clinic, Peptinovo and its core technology, PALM™ (Peptide-Amphiphile Lipid Micelle),